A medical device company formed by a group of surgeons to commercialize a surgical suturing device is taking its fight against its former patent lawyer to the federal appeals level, after a lower court dismissed the case.
Patent Infringement
Texas judge gives, takes away from Smith & Nephew in Arthrex patent suit
A federal judge in Texas handed Smith & Nephew (NYSE:SNN) a mixed blessing in its ongoing patent infringement fracas with Arthrex Inc., granting an injunction against further infringement but giving Arthrex a stay pending appeal.
Philips sues Zoll over AED patents
Koninklijke Philips Electronics N.V. (NYSE:PHG) is suing Zoll Medical Corp. (NSDQ:ZOLL), accusing the Chelmsford, Mass.-based firm of violating a string of automated external defibrillator patents with its AED Plus and AED Pro devices.
The lawsuit, filed in the U.S. District Court for Massachusetts, alleges that Zoll willfully violated the 15 patents despite Philips notifying the company of the alleged infringements in November 2008, according to court documents.
Cambridge scientist creates bloodless blood test
In Iron Man 2, our hero Tony Stark manages to save the world from the military-industrial complex and create an entirely new chemical element, but still suffers through the inconvenient and mildly painful tribulation of numerous pin-prick blood tests a day.
Draper Laboratories, right down the street from Stark’s alma mater, MIT, has a solution. A scientist at the lab has successfully demonstrated an implantable nanosensor that changes color as chemical concentrations fluctuate in the bloodstream.
Boston Scientific files cross-appeal in stent patents suit against Johnson & Johnson
Boston Scientific Corp. (NYSE:BSX) may have won the most recent round in its stent patents war with Johnson & Johnson (NYSE:JNJ), but that didn’t stop the Natick, Mass.-based devices giant from cross-appealing a Delaware judge’s ruling.
The patents in question are at the heart of complicated legal wrangling involving Boston Scientific, its New Brunswick, N.J.-based rival and competitor/partner Abbott (NYSE:ABT). The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the JNJ subsidiary Cordis Corp.’s Cypher.
Medgraph sues Medtronic over glucose monitor patent
A relative bantam is stepping into the patent infringement ring with one of the industry’s heavyweights.
Medgraph Inc., a Rochester, N.Y.-based telemedicine firm, sued Medtronic Inc. (NYSE:MDT), accusing the Minneapolis medical device monolith of patent infringement for its Carelink diabetes management system.
Echo Therapeutics gears up for investor push
Echo Therapeutics Inc. (OTC:ECTE) is gearing up for a push to land new investors next year, which it expects to be “transformative,” hiring a New York-based investor relations consulting firm to manage a “strategic investor relations campaign.”
Hayden IR will develop and implement the Franklin, Mass.-based company’s bid to attract more investors in 2010. Echo is developing needle-free drug delivery technologies, including a non-invasive, wireless glucose monitoring device and skin preparation system for transdermal drug delivery.
Echo Therapeutics scores an extra $562,000 in Philly
Echo Therapeutics Inc. (OTCBB:ECTE) wrapped up its latest fund-raising effort this week, tapping into the old-money network in and around the City of Brotherly Love.
Echo Therapeutics releases positive glucose monitor study results
Echo Therapeutics Inc. (ECTE) is touting preliminary results of a clinical trial of its Symphony tCGM Biosensor glucose monitor in patients with Type I and Type II diabetes.
Echo Therapeutics drums up $3 million
Echo Therapeutics Inc. (ECTE) drummed up about $3 million in a private stock sale.
The Franklin, Mass.-based company, which is developing a non-invasive, wireless transdermal continuous glucose monitoring system, said it sold roughly 2.37 million share for $1.25 each, and issued about 2.2 million warrants with a $2.00 exercise price.
Echo Therapeutics begins clinical study of transdermal glucose monitor
Echo Therapeutics Inc. will complete a clinical study of its Symphony non-invasive, wireless transdermal continuous glucose monitoring system by the fourth quarter, in what would be a major step forward for a company that has burned through more than $60 million trying to bring its products to market.